Modulation of immunologic responses to HIV-1(MN) recombinant gp160 vaccine by dose and schedule of administration

Vaccine

Volumn 16, Issue 5, 1998, Pages 493-506

  Gorse, Geoffrey J ^a   McElrath, M Julie ^b   Matthews, Thomas J ^c,k   Hsieh, Ray Hahn ^d   Belshe, Robert B ^a   Corey, Lawrence ^b   Frey, Sharon E ^a   Kennedy, Donald J ^a   Walkerl, Mary Clare ^e   Eibl, Martha M ^f   Schwartz, David ^g   Clemen, Mary Lou ^g   Mulligan, Mark ^h   Mestecky, Jiri ^h   Jackson, Susan ^h   Hook, Edward ^h   Keefer, Michael C ⁱ   Dolin, Raphael ⁱ   Graham, Barney S ^j   Wright, Peter ^j   Weinhold, Kent ^k   Bolognesi, Dani ^k   Savarese, Barbara ^e   McNamara, James G ^e   Fast, Patricia E ^e   more..

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMMES CORPORATION   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f BAXTER HEALTHCARE CORPORATION   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k DUKE UNIVERSITY   (United States)

more..

Author keywords

Cytokines; HIV 1(MN) envelope glycoprotein; Immune response; Immunoglobulin subclasses; Neutralizing antibody; Vaccine

Indexed keywords

CYTOKINE; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 6844241969     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)80003-5     Document Type: Article

References (63)

1. 1 Dolin, R., Graham, B.S. and Greenberg, S.B. et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann. Intern. Med. 1991, 114, 119-127.
2. 2 Kovacs, J.A., Vasudevachari, M.B. and Easter, M. et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV seronegative volunteers by immunization with recombinant gp160. J. Clin. Invest. 1993, 92, 919-928.
3. 3 Keefer, M.C., Graham, B.S. and Belshe, R.B. et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res. Hum. Retroviruses 1994, 10, 1713-1723.
4. 4 Belshe, R.B., Clements, M.L. and Dolin, R. et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 HIV-1 vaccine in low risk volunteers. J. Infect Dis. 1993, 168, 1387-1395.
5. 5 Gorse, G.J., Schwartz, D.H. and Graham, B.S. et al. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin. Exp. Immunol. 1994, 98, 178-184.
6. IIIB rgp120 subunit vaccine. Lancet 1993, 342, 69-73.
7. 7 Graham, B.S., Keefer, M.C. and McElrath, M.J. et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adult volunteers: recombinant envelope glycoprotein gp120. Ann. Intern. Med. 1996, 125, 270-279.
8. 8 McElrath, M.J., Corey, L., Clements, M.L et al. A phase II HIV prophylactic vaccine trial in seronegative volunteers: expanded safety and immunogenicity evaluation of two recombinant gp120 vaccines. Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL. American Society for Microbiology, Washington, DC, 1994, p. 238, abstract 1241
9. 9 Belshe, R.B., Graham, B.S. and Keefer, M.C. et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994, 272, 475-480.
10. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 1994, 170, 1288-1291.
11. 11 Cooney, E.L., McElrath, M.J. and Corey, L. et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. USA 1993, 90, 1882-1886.
12. 12 Graham, B.S., Matthews, T.J. and Belshe, R.B. et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 1993, 167, 533-537.
13. 13 Walker, M.C. and Fast, P.E. Clinical trials of candidate AIDS vaccines. AIDS 1994, 8, (S1), S213-S236.
14. 14 Putney, S.D., Javaherian, K., Rusche, J., Matthews, T. and Bolognesi, D.P. Features of the HIV envelope and development of a subunit vaccine. In: Vaccine Research and Clinical Trials (Eds Putney, S.D. and Bolognesi, D.P.). Marcel Dekker, New York, 1990, pp. 3-61.
15. 15 Gorse, G.J., Patel, G.B., Newman, F.K., Mandava, M., Belshe, R.B. and for the NIAID AIDS Vaccine Clinical Trials Network, Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. Vaccine 1995, 13, 1170-1179.
16. 16 Gorse, G.J., Belshe, R.B., Newman, F.K., Frey, S.E. and the NIAID AIDS Vaccine Clinical Trials Network, Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 1992, 10, 383-388.
17. 17 Takahashi, H., Nakagawa, Y. and Pendleton, C.D. et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 1992, 255, 333-336.
18. 18 Keefer, M.C., Bonnez, W., Roberts, N.J. Jr., Dolin, R. and Reichman, R.C. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J. Infect. Dis. 1991, 163, 448-453.
19. 19 Stanhope, P.E., Clements, M.L. and Siliciano, R.F. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J. Infect. Dis. 1993, 168, 92-100.
20. 20 Hammond, S.A., Bollinger, R.C. and Stanhope, P.E. et al. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CDS+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 1992, 176, 1531-1542.
21. 21 Stanhope, P.E., Liu, A.Y., Pavlat, W., Pitha, P.M., Clements, M.L. and Siliciano, R.F. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J. Immun. 1993, 150, 4672-4686.
22. 22 Orentas, R.J., Hildreth, J.E.K. and Obah, E. et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990, 248, 1234-1237.
23. 23 El-Daher, N., Keefer, M.C., Reichman, R.C., Dolin, R. and Roberts, N.J. Jr. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J. Infect. Dis. 1993, 168, 306-313.
24. 24 Mascola, J.R., Snyder, S.W. and Weislow, O.S. et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 1996, 173, 340-348.
25. 25 Mannhalter, J.W., Fischer, M.B. and Wolf, H.M. et al. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells. J. Infect. Dis. 1995, 171, 437-440.
26. 26 Berman, P.W., Gregory, T.J. and Riddle, L. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345, 622-625.
27. 27 Fultz, P.N., Nara, P. and Barré-Sinoussi, F. et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256, 1687-1690.
28. 28 Barrett, N., Eder, G., and Dorner, F. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees. Biotechnol. Ther. 1990-91, 2, 91-106.
29. 29 Girard, M., Meignier, B. and Barré-Sinoussi, F. et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 1995, 69, 6239-6248.
30. 30 Berman, P.W., Murthy, K.K. and Wrin, T. et al. Protection of MN-rgp120Hmmunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 1996, 173, 52-59.
31. SF2. AIDS 1995, 9, 1313-1322.
32. 32 Gorse, G.J., Rogers, J.H. and Perry, J.E. et al. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. Vaccine 1995, 13, 209-214.
33. 33 Gorse, G.J., Yang, E.Y., Belshe, R.B., Berman, P.W. and for the NIAID AIDS Vaccine Evaluation Group. Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. Clin. Diagn. Lab. Immunol. 1996, 3, 769-773.
34. 34 Belshe, R.B., Clements, M.L. and Dolin, R. et al. Interpretation of serodiagnostic tests for HIV in the 1990s: impact of HIV vaccine studies in uninfected volunteers. Ann. Intern. Med. 1994, 121, 584-589.
35. 35 Barrett, N., Mitterer, A. and Mundt, W. et al. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retroviruses 1989, 5, 159-171.
36. 36 Gorse, G.J., Frey, S.E., Newman, F.K., Belshe, R.B. and the NIAID AIDS Vaccine Clinical Trials Network. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. J. Clin. Microbiol. 1992, 30, 2606-2612.
37. 37 Skinner, M.A., Langlois, A.J., McDanal, C.B., McDougal, J.S., Bolognesi, D.P. and Matthews, T.J. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 1988, 62, 4195-4200.
38. 38 Gorse, G.J., Frey, S.E., Patel, G., Newman, F.K., Belshe, R.B. and for the NIAID AIDS Vaccine Clinical Trials Network. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 1994, 12, 912-918.
39. 39 Gorse, G.J., Patel, G.B. and Newman, F.K. et al. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IMB and MN recombinant gp120 vaccines. Clin. Diagn. Lab. Immunol. 1996, 3, 378-386.
40. 40 Mann, D.L., O'Brien, S.J. and Gilbert, D.A. et al. Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res. Hum. Retroviruses 1989, 5, 253-255.
41. 41 Popovic, M., Read-Connole, E. and Gallo, R.C. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 1984, 2, 1472-1473.
42. 42 Popovic, M., Sarngadharan, M.G., Read, E. and Gallo, R.C. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.
43. 43 Gallo, R.C., Salahuddin, S.Z. and Popovic, M. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS. Science 1984, 224, 500-503.
44. 44 Shaw, G.M., Hahn, B.H., Arya, S.K., Groopman, J.E., Gallo, R.C. and Wong-Staal, F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984, 226, 1165-1170.
45. 45 Ratner, L., Haseltine, W. and Patarca, R. et al. Complete nucleotide sequence of the AIDS virus HTLV-III. Nature (London) 1985, 313, 277-284.
46. 46 Starcich, B.R., Hahn, B.H. and Shaw, G.M. et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986, 45, 637-648.
47. 47 Boyum, A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 1968, 21, (suppl. 97), 77-89.
48. 48 Gorse, G.J. and Belshe, R.B. Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand. J. Infect. Dis. 1991, 23, 7-17.
49. 49 Scott, M.G., Briles, D.E. and Nahm, M.H. Selective IgG subclass expression: biologic, clinical and functional aspects. In: The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation (Ed. Shakib, F.). Pergamon Press, Oxford, 1990, pp. 161-183
50. 50 Jefferis, R. Structure-function relationships of IgG subclasses. In: The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation (Ed. Shakib, F.). Pergamon Press, Oxford, 1990, pp. 93-108
51. 51 Anderson, C.L. and Looney, R.J. Human leukocyte IgG Fc receptors. Immunol. Today 1986, 7, 264-266.
52. 52 Lawrence, D.A., Weigle, W.O. and Spiegelberg, H.L. Immunoglobulins cytophilic for human lymphocytes, monocytes and neutrophils. J. Clin. Invest. 1975, 55, 368-376.
53. 53 Kovacsovics-Bankowski, M., Carini, C., Kashala, O. and Essex, M. Isotypic distribution of HIV-1-specific antibodies in individuals from Central Africa. Viral Immunol. 1992, 5, 243-248.
54. 54 Broliden, P.A., Morfeldt-Mansson, L., Rosen, J., Jondal, M. and Wahren, B. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients. Clin. Exp. Immunol. 1989, 76, 216-221.
55. 55 Khalife, J., Guy, B. and Capron, M. et al. Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res. Hum. Retroviruses 1988, 4, 3-9.
56. 56 Skvaril, F. IgG subclasses in viral infections. Monogr. Allergy 1986, 19, 134-143.
57. 57 Hammarström, L. and Smith, C.I.E. Subclass restrictions of IgG antibody responses. In: The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation (Ed. Shakib, F.). Pergamon Press, Oxford, 1990, pp. 301-312
58. 58 Mathiesen, T., Persson, M., Sudqvist, V. and Wahren, B. Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separate IgG subclasses 1, 3 and 4 against herpes simplex virus. Clin. Exp. Immunol. 1988, 72, 211-215.
59. 59 Gorse, G.J. Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary. AIDS Res. Hum. Retroviruses 1994, 10, (S2), S141-S143.
60. 60 VanCott, T.C., Polonis, V.R., Loomis, L.D., Michael, N.L., Nara, P.L. and Birx, D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 1995, 11, 1379-1391.
61. 61 Zolla-Pazner, S., Alving, C. and Belshe, R.B. et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J. Infect. Dis. 1997, 175, 764-774.
62. 62 Flores-Romo, L., Millsum, M.J., Gillis, S., Stubbs, P., Sykes, C. and Gordon. J. Immunoglobulin isotype production by cycling human B lymphocytes in response to recombinant cytokines and anti-IgM. Immunology 1990, 69, 342-347.
63. 63 Clerici, M. and Shearer, G.M. A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol. Today 1993, 14, 107-111.